Format

Send to

Choose Destination
Hum Gene Ther. 2017 Nov;28(11):1061-1074. doi: 10.1089/hum.2017.150.

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.

Author information

1
1 Department of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern Finland , Kuopio, Finland.
2
2 INSERM UMR 1089, Université de Nantes , CHU de Nantes, Nantes, France.
3
3 Genethon and IMSERM U951 , Evry, France.
4
4 University Pierre and Marie Curie and INSERM U974 , Paris, France .

Abstract

Over the past decade, vectors derived from adeno-associated virus (AAV) have established themselves as a powerful tool for in vivo gene transfer, allowing long-lasting and safe transgene expression in a variety of human tissues. Nevertheless, clinical trials demonstrated how B and T cell immune responses directed against the AAV capsid, likely arising after natural infection with wild-type AAV, might potentially impact gene transfer safety and efficacy in patients. Seroprevalence studies have evidenced that most individuals carry anti-AAV neutralizing antibodies that can inhibit recombinant AAV transduction of target cells following in vivo administration of vector particles. Likewise, liver- and muscle-directed clinical trials have shown that capsid-reactive memory CD8+ T cells could be reactivated and expanded upon presentation of capsid-derived antigens on transduced cells, potentially leading to loss of transgene expression and immune-mediated toxicities. In celebration of the 25th anniversary of the European Society of Gene and Cell Therapy, this review article summarizes progress made during the past decade in understanding and modulating AAV vector immunogenicity. While the knowledge generated has contributed to yield impressive clinical results, several important questions remain unanswered, making the study of immune responses to AAV a priority for the field of in vivo transfer.

KEYWORDS:

AAV vectors; T cells; antibody responses; gene therapy; immune responses

PMID:
28835127
PMCID:
PMC5649404
DOI:
10.1089/hum.2017.150
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center